Immunotherapies, such as programmed cell death-1 or programmed cell death-ligand 1 inhibitors, also demonstrate encouraging clinical benefits including response rate, and the immune checkpoint represent a useful target to enhance tumor regression (33, 34). The gene discussed is PDCD1; the disease is neoplasm.